Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (October 2015)
39 slides from Fluoropharma Medical's investor presentation, Oct 16, 2015
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Flue ee anne Enabling Personalized Medicine Through Precision Diagnostics (OTCQB:FPMI)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contain: i ” withit Securities Act of 1933, as amended 1934, as amended, and the Private Securities itigation Reform Act of 1995, whic i he safe harbor created thereby. feats “expects,” “intends, Qu cal plans,” “projects,” “believes,” “estimates,” ite nag
Slide 3: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance THE COMPANY CORE EXPERTISE TWO ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS from Massachusetts General Hospital diagnostic testing BFPET = = Cardiac blood flow CardioPET => Cardiac viability assessment Higher diagnostic accuracy Alternative to invasive p
Slide 4: ...People will die of heart disease
...People will die of heart disease «Anew heart attack occurs Sea eee a is performed www.FluoroPharma.com
Slide 5: Coronary Disease by the Numbers
Coronary Disease by the Numbers * 69% of US adults are overweight or obese * Only 50% of Americans meet physical activity guidelines ¢ More than 100 million US adults have high cholesterol ¢ 80 million US adults have high blood pressure * Cardiovascular procedures and operations increased 28% from 2
Slide 6: Cardiovascular Disease is a Major Global Health Burden
Cardiovascular Disease is a Major Global Health Burden Pharma i aa Coronary Artery Disease (CAD) ' KEY FACTS - US AND WW: WHO: ‘Neglected Global Epidemic’ low / middle income countries . ee} in China, % in etree 's US: top cause (38.5%) KEY UNMET NEE! ‘Acute Myocardial infarction (MI) Malignai Conge
Slide 7: Heart Failure is Reaching Epidemic Proportions
leart Failure is Reaching Epidemic Proportions ~70% of pet is ean) by ischemic heart dis The average life expectancy after HF diagnosis is 8 years, but 50% die within 5 HF prevalence is expect increase 46% from one is ae Total cost in 2012 was $30.7 billion; Hospitalization rates are increasing in p
Slide 8: FluoroPharma Medical Inc. Development Portfolio
FluoroPharma Medical Inc. Development Portfolio Potential fo become the new For diagnosis of acute and chronic “standard? for measuring cad cardiovascular blood flow * For use in combination wi = Detects regions of fatty acid stress-testing in pallens with uptake for metabolism presumptive chronic C
Slide 9: January 2015
Tanvary 2015 www.FluoroPharma.com
Slide 10: www.FluoroPharma.com
www.FluoroPharma.com
Slide 11: Molecular Pharma
Molecular — Pharma
Slide 12: Coronary Artery Disease (CAD) Treatment Flow Model
Coronary Artery Disease (CAD) Treatment Flow Model Unclognosed CAD Patient Interisy Gener Evaluation www.FluoroPharma.com Le TOTO STITT ETI er pecs ty Pa Dr ia elie ice
Slide 13: Patients With Known CAD
ients With Kno\ StressiRee Ee ity Imaging ess induced Seo * Hieron, Stunning + LV fun More invasive Less invasive www.FluoroPharma.com
Slide 14: BFPET Clinical Use
BFPET Clinical Use MYOCARDIAL PERFUSION IMAGING + Evaluate patients with known or suspected CAD CURRENT DIAGNOSTIC TEST 82) CUNIGAL: NEED + SPECT imaging has ~75% diagnostic accuracy + 10% of “normal” SPECT pais were found to be “abnormal” on PET# “40-50% of perfusion scans should be done Greatest m
Slide 15: BFPET Phase Observations
BFPET Phase 1 Observations Phase I trial for BFPET (US) Co eee . Baie 12 healthy volunteers 5 20-85 + Noadverse events No clinically significant changes ‘noted in follow-up clinical and laboratory testing, BFPET images have higher resltlon thn gold standard ona ualitative basi www.FluoroPharma.com
Slide 16: BFPET Study
BFPET IIT Sti www.FluoroPharma.com
Slide 17: PPV and NPV comparison: SPECT vs BFPET
PPV and NPV ther ism SPECT. | | BFPET On SPECT this patient appeared to ...While BFPET clearly showed that have a defect.. was: this pati a anys elma all www.FluoroPharma.com
Slide 18: Physicians have expressed a strong willingness to utilize BFPET
Physicians have expressed a strong willingness to utilize BFPET Fluore < Pharma Key Takeaways From Cardiologist and @ patients ¥ Two clinicians indicated they would use BFPET for 100% of newly presented IHD patients 2 ° Postve Negatne Neutral identify early Ischemic Heart Disease (IHD) @ BFPET _* No
Slide 19: The BFPET Opportunity: United States
The BFPET Opportunity: United States Market Procedures "St: PET Market Size poster Baan 42 million 5.0 milion D Projected BFPET Scans “3 Projected BFPET Revenue MILLIONS. 40 SeLiONs 50 3s 40 30 2s 30 il 2 6 | 10 10 | = | oo | 00 Years Years Years veers veor3 Years 2A www.FluoroPharma.com
Slide 20: FCPHA (CardioPET) Preliminary Results
FCPHA (CardioPET) Pré 18e ‘OH Fatty acid Cee that detects regions of metabolic insufficiency (45 NHV and 6 CAD patients) ardioPET promising safety with no AEs detected . + Ginval findings consistent with MPI SPECT + Qua ality of CardioPET images visually superior to MPI SPECT liminary Results © {vie
Slide 21: CardioPET may provide direction in the evaluation of Acute Coronary Syndrome
CardioPET may rovide direction in the evaluation of Acute Coronary Syndrome (ACS) Patient Presents to ED With Symptoms Suggestive of ACS ED Conducts Diagnostic Tests—Patient History, Chest. X-Ray, ECG, Biomarkers (Enzymes) trong. ~6.4M ‘ ‘ sie ; Definite ACS Non-Cardiac Diagnosis Aamo hosp panto nos
Slide 22: Cardiac Metabolism
Cardiac Metabolism Cardiac PET: AVE vette Quantitative ieee Tool for Heart Failure inagem Myocardial FA/CHO Fuel Mix Lipotoxie <— Physiological ——» — Glucotoxic Under physiological cor tion. Excessive reliance 25 glucolipotoicty (69). www.FluoroPharma.com
Slide 23: Fatty Acid Metabolism at the Intersection of Diabetes and Heart Disease
Fatty Acid ee is at ne Intersectio! rt F of Diabetes and Hi ISE Tee WYPORLYGEMIA DIABET ny www.FluoroPharma.com
Slide 24: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Pharma heart disease hold greatest promise reducing the overall costs of healthcare fental healt ironic lung disease 4% End-stage renal disease 3% ‘ancer, Base = 289 Alzheimer's disease Stroke 7 Sour: HeatnLzed www.FluoroPharma.com 26 300 Top Health System E
Slide 25: Phase II CardioPET Data is Emerging
Phase II CardioPET Data is Emerging CardioPET PHASE Il STUDY CardioPET PHASE II STUDY www.FluoroPharma.com
Slide 26: SNMMI Data on CardioPET Quantitation (1/2)
SNMMI Data on CardioPET Quantitation (1/2) Objective: The labeled fatty acid, trans-9(AS}-#F-uoro-3,4(R5,RS) methyleneheptadecanoic acid ("*F-FCPHA / CardioPET) has completed a Phase I clinical tral evaluating its aa Jesunab ‘and dosimetry. "F-FCPHA is currently undergoing Phase II evaluation in pat
Slide 27: SNMMI Data on CardioPET Quantitation (2/2)
SNMMI Data on CardioPET Quantitation (2/2) onezonpanneniiaameteanader paperanian atom = Stas Sconao wmagesttome2 somiautesswere <Srpueewcoresondngs-TeMBESrTS 5 Images Fomrdmonesaiusneesess Fm riusenfccishntheaomeareavarSPecTomace — tn i Conprorteroonie2 C2 nodetinsneratzandsasnppat ine sro reser mat
Slide 28: Preliminary Imaging Performance: PET vs. SPECT
Preliminary Imaging Performance: PET vs. SPECT, ~ Pharma IMAGES THAT TEACH Peg Cabelas EET Sacer for Fete ec elealinng a fatty acid uptake in flan Demat. MO Mana, Crue MDS Mae! esie 0. region: out abnormalities on SET assem cece Fatty acid uptake and retention may be better ema et the quantitative c
Slide 29: Coronary Flow Reserve: Clinical Implications
Coronary Flow Reserve: Clinical Implications je it ia, Rubidium The Ischemic Flow Action Threshold Maximum dilatation Medium motabotsm Low metaboism 5 & & Coronary low, mL/min per g myocardium 0 20 40 60 80 100 120 140 160 180 scoronicod bresse 1 Maps and Range of Abnormalities in ‘© cument Medicine
Slide 30: CardioPET Clinical Use
CardioPET Clinical Use DIAGNOSIS OF CAD AT REST Evaluate CAD in angina and palinis that cannot exercise CARDIAC VIABILITY ASSESSM| a a MYOCARDIAL PERFUSION CURRENT TREATMENT Invasive coronary angiography and PCI cuNican NEED 1.3 million diagnostic angiography procedure at $26,000 and 1.3 million PCI
Slide 31: Estimated PET Market Procedures and Projected CardioPET Revenue
Fluoro _— Pharma Est. PET Market Market Procedures Procedures CAD diagnosis at rest. 3.8 milion A million Cardiac vied 4.6 milion 5 milion assessment Myocardial perfusion 42 millon 6 million Courtesy of Fobian Demeure, UL, Belgium imaging Projected CardioPET Revenue Projected CardioPET Scans Year3,
Slide 32: Substantial PET Installed Base in the US
Substantial PET Installed Base in th a2 ie US. 800 Scanners Operating at ~40% Capacity Distribution of PET Machines in US Hospitals*
Slide 33: PET Manufacturing and Distribution
PET Manufacturing and Distribution ‘Administration—Hospital (Nuclear Medicine/Radiology) GMP Manufacturing > Precursor Manufacturing: FluoroPharma contacts with a (qualified manufacturer for Production of"precursor Production of Finished Materia Manufacturer recy spe procurza'o ron facies Et inched
Slide 34: Production of Finished Material
Production of Fil Tl f Finished Materia he US Has an Established Cyclotron Di high te Approximately 100 FDG pro bution Network Zovace/IBA Nolecuar @ Cardinal Heath Oy © Pemer c platen Management areement
Slide 35: The Changing Paradigm in Healthcare
The Changing Paradigm in Healthcare PAST FUTURI Fragmented 5 4 5 4 vs 5 2 5 4 vo wea, systems of care volders; re Decisions by individual ste Cats) rolder networks Decisions by nv (ill Aligned (W) Conventional (Complex Multi-stakehotd Ages Predominant HCP ee 10 (outinoal prescbers coordinated networ
Slide 36: Drivers of Referrals to Cardiac PET
Drivers of Referrals to Cardiac PET Drivers and Benefits: © Meeting today’s clinical needs Lower radiation dose Improved diagnostic accuracy Improved patient outcomes Craton of anatomical and functional studies 15 See image quality | Improved quantification possible 5 | 0! raster Throughput Catheriz
Slide 37: Why PET, and Why Now
hy PET, ai Wh d Why Now. Quality, races and increasing installed base Rueapascasan 1es improvement Paradigm shift to “ret Seccaneias niaher mataeh sarees ate sensitivity than SPECT PREPARE ay provide 2 more accurate diagnosis fr patients, potential reducing unnecessary downstream procedures istribut
Slide 38: Investment Highlights
Investment Highlights hase 2 + Short Study Timelines/regulatory pathway + Early data demonstrates favorable imaging characteristics Pis une in the Molecular Imaging domain + Intellect advantages ote PET versus SPECT + Higher res + Better angiography + Less pala radiation exposure + Establist heal La
Slide 39: Enabling Personalized Medicine Through Precision Diagnostics
Flue ee anne Enabling Personalized Medicine Through Precision Diagnostics (OTCQB:FPMI)
FluoroPharma Medical — Investor Presentation (October 2015) on 6ix